DF/HCC Renal Cancer SPORE

DF/HCC 肾癌孢子

基本信息

批准号：
7644693
负责人：
Michael Benjamin Atkins
金额：
$ 116.53万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-18 至 2009-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7644693
关键词：
Address Affect Allogenic Angiogenesis Inhibitors Animal Model Antigens Apoptosis Area Arts Autologous Dendritic Cells Autologous Tumor Cell Award Bilateral Binding Bioinformatics Biological Biological Assay Biological Markers Biology Biometry Bladder Blood Vessels Blood flow CCI-779 Cancer Center Cancer Vaccines Carcinoma in Situ Caring Cell Line Cell Proliferation Cell fusion Cells Clear Cell Clinic Clinical Clinical Data Clinical Pathology Clinical Research Clinical Trials Coagulation Process Collaborations Communities Complement Contralateral Conventional (Clear Cell) Renal Cell Carcinoma Correlation Studies Cytolysis Dana-Farber Cancer Institute Data Data Correlations Data Set Dendritic Cells Development Disease Disease Progression Disease regression Dose Early Diagnosis Effectiveness Endothelial Cells Epidermal Growth Factor Receptor European Evaluation Excision Exhibits Family Funding Future Gene Expression General Hospitals Generations Genes Genetic Goals Grant Growth Factor Growth Factor Receptors Head Hospitals Hypoxia Inducible Factor Image Immune Immune Targeting Immunity Immunologic Monitoring Immunologics Immunotherapy In Situ Hybridization In Vitro Institutes Interferons Interleukin-12 Interleukin-2 Invasive Investigation Israel K-Series Research Career Programs Kidney Knowledge Laboratories Lead Local Therapy Localized Disease Lung Magnetic Resonance Imaging Malignant neoplasm of kidney Massachusetts Mediating Medical Oncologist Medical center Methods Microscopic Modality Modeling Molecular Monitor Mutation Nature Neoplasm Metastasis Nephrectomy Other Therapy Outcome PTK787 PTK787/ZK 222584 Pathologic Pathology Pathway interactions Patients Pediatric Hospitals Performance Perfusion Pharmaceutical Preparations Pharmacologic Substance Phase Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Plasma Platelet-Derived Growth Factor Platelet-Derived Growth Factor Receptor Play Population Predisposition Principal Investigator Productivity Proteomics Public Health Schools Radiofrequency Interstitial Ablation Reaction Time Receptor Protein-Tyrosine Kinases Recording of previous events Recurrence Recurrent disease Refractory Relapse Renal Cell Carcinoma Renal carcinoma Reporting Reproduction spores Research Research Personnel Research Priority Resistance Resources Rewards Risk Role Sampling Science Screening procedure Series Serum Serum Markers Signal Pathway Signal Transduction Skates Skating Solid Neoplasm Specialized Program of Research Excellence Specific qualifier value Specimen Staging Standards of Weights and Measures Surface T-Cell Proliferation T-Lymphocyte TNF gene Techniques Testing Therapeutic Thinking Time TimeLine Tissues Toxic effect Transgenic Organisms Translational Research Translations Treatment outcome Tumor Antigens Tumor Debulking Tumor Suppressor Genes Tumor Tissue United States Food and Drug Administration United States National Institutes of Health Urine Urologist Vaccination Vaccines Validation Vascular Endothelial Growth Factors Von Hippel-Lindau Syndrome Woman Work Xenograft procedure anergy angiogenesis authority autocrine base cancer therapy carcinogenesis clinical efficacy cohort cost design gain of function heterokaryon human study immune function improved in vitro Assay in vivo inhibitor/antagonist insight interest kidney cell loss of function member mouse model neoplastic cell novel novel strategies outcome forecast paracrine preclinical study prognostic programs protein expression radiofrequency receptor research study response restoration size small molecule software development tool translational clinical trial translational study treatment program tumor tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence in Renal Cancer originating from the Renal Cancer Program-in-Development of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Renal Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Identification of markers for early detection and monitoring of high-risk RCC populations; 2) Inhibition of VHL-regulated growth factor pathways for treatment of RCC; 3) Combination radiofrequency ablation and antivascular/anitangiogenesis therapy for RCC; 4) Identification of molecular and immunologic correlates of RCC prognosis and responsiveness to therapy, and 5) Dendritic cell/tumor fusions in conjunction with IL-12 as novel immunotherapy for RCC. These projects are integrated by four cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; 3) Tissue Acquisition, Pathology and Clinical Data, and 4) Monitoring. This SPORE application outlines a Developmental Projects Program which includes a plan for selection and review of projects, and eight sample projects that could be considered for support. We also include a Career Development Award Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Renal Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with renal cancer.

描述（由申请人提供）：此申请代表了创建一个专业的肾癌研究卓越研究计划，该计划源自新配置的Dana-Farber Harvard Cancer Center（DF/HCC）和Beth Israel Deaconess Medical Center的新配置的Dana-Farber Harvard Cancer Center（DF/HCC）。 DF/HCC肾癌孢子包括来自哈佛大学的所有医院的研究人员 - 贝丝以色列女执事医疗中心，达纳 - 弗尔伯癌研究所，马萨诸塞州综合医院，布里格姆和妇女医院以及儿童医院医院以及哈佛公共卫生学院。通过此应用程序支持了五个主要项目，包括：1）标记以早期检测和监测高风险RCC人群的标记； 2）抑制VHL调节的生长因子途径用于治疗RCC； 3）RCC的射频消融和抗血管/抗血管生成疗法； 4）鉴定RCC预后和对治疗的反应性的分子和免疫学相关性，以及5）与IL-12结合使用的树突状细胞/肿瘤融合作为RCC的新型免疫疗法。这些项目由四个核心整合。这些是：1）行政，评估和计划； 2）生物统计学； 3）组织采集，病理和临床数据以及4）监测。该孢子应用程序概述了一个开发项目计划，其中包括选择和审查项目的计划，以及八个可以考虑支持的示例项目。我们还包括一项职业发展奖计划，概述了肾脏癌的才华横溢的年轻调查人员的识别，支持和审查的机制。 DF/HCC肾脏癌孢子的总体目标是将生物学和技术进步转化为肾脏癌患者临床意义的进展。